1 / 47

Learning Objectives

Learning Objectives. Variable Response to Clopidogrel. Platelet Reactivity and Outcomes . Clopidogrel Metabolism. CYP450 Genetic Variants and PK/PD. CYP2C19 and Clinical Outcomes. Clopidogrel Boxed Warning. CYP2C19 and Treatment With Clopidogrel.

branxton
Download Presentation

Learning Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Learning Objectives

  2. Variable Response to Clopidogrel

  3. Platelet Reactivity and Outcomes

  4. Clopidogrel Metabolism

  5. CYP450 Genetic Variants and PK/PD

  6. CYP2C19 and Clinical Outcomes

  7. Clopidogrel Boxed Warning

  8. CYP2C19 and Treatment With Clopidogrel

  9. CURRENT-OASIS 7: Study Design, Flow, and Compliance

  10. CURRENT-OASIS 7: Clopidogrel Double (600 mg  150 mg/d x 7d  75 mg/d) vs Standard Dose (300 mg  75 mg/d)

  11. CURRENT-OASIS 7: Clopidogrel Double- vs Standard-Dose Bleeding PCI Population

  12. Tailoring Clopidogrel Dosing With Platelet Function Monitoring

  13. GRAVITAS Study Design

  14. GRAVITAS Primary End Point: CV Death, MI, Stent Thrombosis

  15. GRAVITAS Pharmacodynamics: Effect of SD vs HD Clopidogrel

  16. PRINCIPLE TIMI 44 PRIMARY EP: Acute Phase

  17. PRINCIPLE TIMI 44 PRIMARY EP: Maintenance Phase

  18. TRITON-TIMI 3813,608 Patients With ACS and Planned PCI Randomized to Prasugrel (60/10) vs Clopidogrel (300/75)

  19. TRITON-TIMI 38 Bleeding Events: Safety Cohort (N = 13,457)

  20. TRILOGY-ACS Study Design

  21. TRILOGY-ACS: Primary Efficacy End Point to 30 Months (Age < 75 years)

  22. Ticagrelor Pharmacodynamics

  23. Platelet Reactivity: Ticagrelor vs Prasugrel

  24. PLATO Primary Efficacy End Point: CV Death, MI, or Stroke

  25. PLATO: Bleeding

  26. TRA-CER Primary End Point:CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

  27. TRA-CER: Bleeding Outcomes

  28. CHAMPION PHOENIX Study Design

  29. CHAMPION PHOENIX: Primary Efficacy Outcomes at 48 Hours, MITT

  30. CHAMPION PHOENIX: Non-CABG Bleeding at 48 Hours

  31. ESC NSTE-ACS Guidelines

  32. Periprocedural Antithrombotic Medication in Primary PCI

  33. Antiplatelet Therapy in UA/NSTEMI

  34. Antiplatelet Therapy to Support Primary PCI for STEMI

  35. Case 1

  36. Case 2

  37. Case 3

  38. Conclusions

  39. Abbreviations

  40. Abbreviations (cont)

  41. Abbreviations (cont)

  42. Abbreviations (cont)

  43. References

  44. References (cont)

  45. References (cont)

  46. References (cont)

More Related